218 related articles for article (PubMed ID: 16640573)
1. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
2. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463
[TBL] [Abstract][Full Text] [Related]
3. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
5. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.
Ahmad Z; Sharma S; Khuller GK; Singh P; Faujdar J; Katoch VM
Int J Antimicrob Agents; 2006 Dec; 28(6):543-4. PubMed ID: 17101262
[TBL] [Abstract][Full Text] [Related]
6. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
[TBL] [Abstract][Full Text] [Related]
9. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.
Gupta UD; Vemuri N; Gupta P; Kumar V; Tanushree P; Khuller GK
Indian J Med Res; 2015 Sep; 142(3):323-9. PubMed ID: 26458349
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of new enantiomerically pure azole derivatives as inhibitors of Mycobacterium tuberculosis.
Castagnolo D; Radi M; Dessì F; Manetti F; Saddi M; Meleddu R; De Logu A; Botta M
Bioorg Med Chem Lett; 2009 Apr; 19(8):2203-5. PubMed ID: 19299129
[TBL] [Abstract][Full Text] [Related]
12. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
[TBL] [Abstract][Full Text] [Related]
14. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
Kalita A; Verma I; Khuller GK
J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
[TBL] [Abstract][Full Text] [Related]
15. Fighting tuberculosis by drugs targeting nonreplicating
Iacobino A; Piccaro G; Giannoni F; Mustazzolu A; Fattorini L
Int J Mycobacteriol; 2017; 6(3):213-221. PubMed ID: 28776518
[TBL] [Abstract][Full Text] [Related]
16. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.
Milano A; Pasca MR; Provvedi R; Lucarelli AP; Manina G; Ribeiro AL; Manganelli R; Riccardi G
Tuberculosis (Edinb); 2009 Jan; 89(1):84-90. PubMed ID: 18851927
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines.
Protopopova M; Hanrahan C; Nikonenko B; Samala R; Chen P; Gearhart J; Einck L; Nacy CA
J Antimicrob Chemother; 2005 Nov; 56(5):968-74. PubMed ID: 16172107
[TBL] [Abstract][Full Text] [Related]
18. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
Verma RK; Agrawal AK; Singh AK; Mohan M; Gupta A; Gupta P; Gupta UD; Misra A
Tuberculosis (Edinb); 2013 Jul; 93(4):412-7. PubMed ID: 23562366
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Sharma A; Khuller GK; Kanwar AJ; Sharma S
J Infect; 2010 Jun; 60(6):498-501. PubMed ID: 20346970
[No Abstract] [Full Text] [Related]
20. Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice.
Radaeva TV; Nikonenko BV; Mischenko VV; Averbakh MM; Apt AS
Tuberculosis (Edinb); 2005; 85(1-2):65-72. PubMed ID: 15687029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
